retatrutide glp 3 GLP-3 R 30mg Retatrutide GLP-3 | Advanced Triple-Agonist

To view or add a comment, sign in The federal government announced plans to reduce GLP-1 medication costs with direct-to-consumer drug programs, but the impact on employer healthcare plans and pharmacy benefits managers remains uncertain

Retatrutide, an investigational triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly, demonstrated unprecedented weight loss in Phase 2 trials but has not yet completed Phase 3 development

Compounded sublingual drops are liquid formulations of semaglutide or tirzepatide prepared by compounding pharmacies

Of these, GLP-1 RAs are generally preferred because of their demonstrated cardiovascular benefits and potential for improved renal outcomes [2]